| abstract |
The present application relates to a crystallization of a caspase inhibitor, more specifically to (S)-3-((S)-2-(5-(2-chlorophenyl)isoxazole-3-carboxamido)propane Crystallization of amido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)valeric acid, preparation method thereof, crystalline composition thereof, pharmaceutical composition and use thereof. The compound of formula I-A of the present application has high crystal stability and low hygroscopicity, and has advantages in physical properties, safety and metabolic stability, and has high drug value. |